Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369655 · ClinicalTrials.gov registry record · Phase 2
VEGF Trap in Treating Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00369655: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00369655 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00369655, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase II trial is studying how well VEGF Trap works in treating patients with metastatic breast cancer. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor
Interventions
- BIOLOGICAL ziv-aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369655
The ClinicalTrials.gov registry entry for NCT00369655 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ziv-aflibercept is the first listed.
NCT00369655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369655 about?
NCT00369655 is a clinical study titled "VEGF Trap in Treating Patients With Metastatic Breast Cancer". This phase II trial is studying how well VEGF Trap works in treating patients with metastatic breast cancer. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor
What is the current status of trial NCT00369655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2007-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00369655?
The interventions under investigation include: ziv-aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00369655?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.